🔗 Share this article

While the US proceeds with unprecedented adjustments to its vaccine guidelines, one figure appears in a surprising turn: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who first made her name by expressing skepticism about coronavirus vaccinations in the pandemic and has concentrated on potential deaths after COVID-19 vaccination in her short time at the US Food and Drug Administration (FDA).

Scheduled Shifts to Childhood Immunization Schedule

Agency leaders planned to unveil major changes to the pediatric vaccine schedule in December, synchronizing the US with Denmark’s national calendar, sources say – a substantial departure that would place the US at odds with a large portion of the world with insufficient data for public health gain. The announcement has been postponed until the coming year.

In place of the director of the vaccine center, Dr. Høeg is set to speak at the gathering. She was recently named acting director of the FDA’s drug evaluation center, the fifth appointee to head the division this calendar year.

A Shift at the Regulatory Body

The acting appointment might represent a strengthened alliance between the pharmaceutical and biologics branches as Høeg and Prasad strengthen their influence at the regulatory agency – and it signals a renewed priority upon rolling back previously authorized vaccines at the FDA.

The new acting director has often pushed for discontinuing certain pediatric shot schedules in the US in order to be more similar to the Danish model, a society with nationalized medicine and a number of inhabitants roughly the size of the state of Wisconsin.

To date comments, she has persisted in emphasizing on vaccines – typically the purview of Dr. Prasad, director of the FDA’s vaccine center – instead of drug regulation.

Concerns Over Background

The appointee has no obvious background in drug development, oversight or leadership, which has been customary for previous directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the agency head and the vaccine center since spring.

“It seems she lacks to have any of the qualifications” for running the CDER, remarked a neurologist and psychiatrist. “She has not conducted a scientific study. She is not versed in managing a large organization. She lacks background in industry regulation.”

Past heads of CBER would “grasp laws and regulations and the science of medication creation”, commented Janet Woodcock. “Objectively, she doesn’t have the type of experience that prior appointees who ran CBER have had.”

This division has an vast portfolio at the FDA, the former commissioner stated.

“The public just focuses on the innovative therapies, but the generic program authorizes numerous generic medications. There is also a biosimilars division, over-the-counter program and other areas, and each of these must be looked after,” Dr. Woodcock explained. “The responsibility you neglect, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a significant management component to the job, which supervises over 5,000 personnel. “It is a enormous leadership role, if you do it right,” the former official concluded.

Agency Reaction and Contentious Programs

In response to questions about Høeg’s qualifications and whether this selection indicates increased cooperation among regulatory chiefs on vaccines, a spokesperson stated that the “concerns rely on flawed assumptions”.

“Her resume matches the duties of her job,” the spokesperson stated, citing the time Høeg spent advising the FDA commissioner on “medication safety and oversight research, including predictive safety algorithms and shot safety tracking”.

In her interim role, Dr. Høeg inherits the agency head's new priority voucher program, a controversial rapid medication authorization process that apparently concerned her preceding directors. “How are these therapies being picked for this fast-track system? Who makes the decisions?” Dr. Howard questioned. “There’s a lot of secrecy happening at the FDA right now.”

Broadly speaking, he said, “the agency appears to be shifting towards laxer regulations of all drugs, except for immunizations.”

Established Track Record on Vaccines

With vaccines, Dr. Høeg has a more documented, if problematic, track record, critics said. She authored a study using unconfirmed crowd-sourced reports to determine the incidence of heart inflammation following Covid immunization. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who allegedly have changed statistics to imply COVID-19 vaccines are pose a greater threat than they are.

Among her “desired changes” for the current administration encompassed revising regulations for novel immunizations and discontinuing “optional” vaccines, she said post-election on a online show. At the FDA, Høeg has according to sources floated the idea of preventing young men from obtaining COVID-19 vaccines.

“She is an all-around dogmatist who begins with her conclusions and tailors the evidence to retrofit the science in a extremely deceptive, dishonest way,” Dr. Howard said.

Gaining Influence and a “Push for Payback”

Høeg became part of fellow dissenters, {like|